[Giner Soriano M, Gomez Lumbreras A, Ouchi D] Fundació Institut Universitari per a la Recerca a L’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Vedia C] Unitat de Farmàcia, Servei d’Atenció Primària Barcelonès Nord i Maresme, Institut Català de la Salut (ICS), Badalona, Spain. Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Morros R] Fundació Institut Universitari per a la Recerca a L’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. Institut Català de la Salut (ICS), Barcelona, Spain. Plataforma SCReN, UICEC IDIAP Jordi Gol, Barcelona, Spain
IDIAP Jordi Gol
2022-06-10T08:50:08Z
2022-06-10T08:50:08Z
2022-06-08
COVID-19; Anticoagulants orals; Esdeveniments trombòtics; Atenció primària
COVID-19; Oral anticoagulants; Thrombotic events; Primary health care
COVID-19; Anticoagulantes orales; Eventos trombóticos; Atención primaria
Background: The risk of thromboembolic events and COVID-19 complications in anticoagulated patients once hos‑ pitalized has been widely analyzed. We aim to assess these outcomes in primary health care (PHC) patients chronically treated with oral anticoagulants (OAC) in comparison with non-treated. Methods: Cohort study including adults with COVID-19 diagnosis in the PHC records in Catalonia, Spain; from March to June 2020. Patients were matched between exposed and non-exposed to OAC based on age and gender in a 1:2 design. Data source is the Information System for Research in Primary Care (SIDIAP). Results: We included 311,542 individuals with COVID-19. After propensity score matching, we obtained a cohort of 20,360 people, 10,180 exposed and 10,180 non-exposed to OAC. Their mean age was 79.9 and 52.1% were women. Patients exposed to OAC had a higher frequency of comorbidities than non-exposed. Anticoagulated patients had a higher risk of hospital admission (IRR 1.16, 95% CI 1.03–1.29), and of stroke and pulmonary embolism than nonanticoagulated (IRR 1,80, 95% CI 1.06–3.06). The risk of pneumonia was not diferent between groups (IRR 1.04, 95% CI 0.84–1.30). We found a lower risk of death in patients exposed to OAC (IRR 0.60, 95% CI 0.55–0.65). Conclusions: OAC users in our study had more comorbidities and were older than non-users, well known risks for hospitalization being confrmed with our results. We also found in our study that OAC exposure was not associated to an increased risk in the mortality rate, and it was associated with higher risks of hospital admission and thrombo‑ embolic events, although we cannot assess the efect of the interventions applied during hospital admission on the outcomes studied, as our database is a PHC database.
Artículo
Versión publicada
Inglés
Farmacoepidemiologia; Anticoagulants (Medicina) - Efectes secundaris; COVID-19 (Malaltia); DISCIPLINES AND OCCUPATIONS::Natural Science Disciplines::Biological Science Disciplines::Pharmacology::Pharmacoepidemiology; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Hematologic Agents::Anticoagulants; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; DISCIPLINAS Y OCUPACIONES::disciplinas de las ciencias naturales::disciplinas de las ciencias biológicas::farmacología::farmacoepidemiología; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::fármacos hematológicos::anticoagulantes; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus
Springer Nature
BMC Primary Care;23(1)
https://doi.org/10.1186/s12875-022-01752-5
EUPAS Register: EUPAS37205
Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/